TICKERNERD
Menu
IOSPIOSPBasic Materials · Specialty Chemicals

IOSP Stock Forecast: Innospec, Inc. Price Predictions for 2026-2027

Last close, 12 Aug 2026
$93
−0.90% on the day

The 3 Wall Street analysts covering Innospec, Inc. hold a median 12-month price target of $100 — +7.4% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 86 of 100 as at 11 Aug 2026 — inside the top quartile. Here, the model and the Street point the same way.

Market cap
$2.3B
Ticker Nerd rank
86 / 100
Median analyst target
$100
Analysts covering
3
Total return, dividends reinvested
1W
+1.3%
1M
+14.1%
YTD
+23.1%
1Y
+15.3%
From 52W high
−0.9%
From 52W low
+43.0%
$65
$94
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

IOSP stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Innospec, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 11 Aug 2026
86 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Revisions
91
Volatility
88
Value
83
Issuance
80
Quality
73
Growth
61
Momentum
46
Accruals
36
Size
34

Revisions (91): Analysts have, on balance, been raising their forecasts.

Accruals (36): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.

Size (34): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

IOSP stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on IOSP, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$60$70$80$90$100$110Oct 25Jan 26Apr 26Jul 26IOSPHigh $110Median $100Low $93

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

What Wall Street says3 analysts
3 Buy0 Hold0 Sell
Low $93Median $100High $110

The green dot is the last close — the median target sits +7.4% from it.

Recent analyst actionsNewest first
DateFirmActionRatingTarget
18 Nov 2025Freedom Capital MarketsInitiatesBuy$93
21 Apr 2025Seaport GlobalUpgradeBuy—
30 Mar 2022Seaport GlobalInitiatesNeutral—
4 Sept 2019CL KingInitiatesBuy—
12 Apr 2019KeybancDowngradeSector Weight—
12 Apr 2019KeyBancDowngradeSector Weight—
16 Nov 2018KeybancMaintainsOverweight—
16 Nov 2018KeyBancMaintainsOverweight—
13 July 2018KeybancMaintainsOverweight—
13 July 2018KeyBancMaintainsOverweight—
24 Apr 2018Johnson RiceUpgradeBuy—
14 Nov 2017Johnson RiceUpgradeAccumulate—
9 Nov 2017KeybancMaintainsOverweight—
9 Nov 2017KeyBancMaintainsOverweight—
9 Nov 2017Monness Crespi HardtDowngradeNeutral—
9 Nov 2017Monness, Crespi, HardtDowngradeNeutral—
22 Aug 2017Monness Crespi HardtUpgradeBuy—
22 Aug 2017Monness, Crespi, HardtUpgradeBuy—
19 Dec 2016Monness Crespi HardtDowngradeNeutral—
19 Dec 2016Monness, Crespi, HardtDowngradeNeutral—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. IOSP appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Estimates

IOSP analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
EPS revision, 90 days
−0.1%
Analysts raising
1
Analysts cutting
1
Fundamentals

Innospec, Inc. (IOSP) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
19.1×

Cheaper than 40% of US stocks

Price / sales
1.3×

Cheaper than 65% of US stocks

Price / book
1.7×

Cheaper than 52% of US stocks

EV / EBITDA
11.0×

Cheaper than 35% of US stocks

Growth & margins
Revenue growth (YoY)
11.8%

Higher than 57% of US stocks

Earnings growth (YoY)
31.1%

Higher than 67% of US stocks

Gross margin
28.1%

Higher than 32% of US stocks

Operating margin
8.1%

Higher than 61% of US stocks

Net margin
6.6%

Higher than 64% of US stocks

Returns & dividend
Return on equity
9.1%

Higher than 61% of US stocks

Return on assets
5.1%

Higher than 77% of US stocks

Dividend yield
2.0%

Higher than 45% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Peers

IOSP vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSpecialty Chemicals
CompanyMarket capTKN rank
IOSPInnospec, Inc.$2.3B
86
MTXMinerals Technologies, Inc.$2.3B
70
CCThe Chemours Co.$2.2B
57
HWKNHawkins, Inc.$2.7B
69
STDNStandard Nuclear, Inc.$1.9B
1
NGVTIngevity Corp.$2.8B
99
KWRQuaker Houghton$2.9B
87

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Innospec, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest IOSP news & analysis

Innospec: Topline Is Growing As Expected

Seeking Alpha · 12 Aug 2026neutral

Innospec's topline grew as expected in Q2 2026, with revenue up 12% and beating estimates by $34.17 million, led by the oilfield segment's DRA adoption and re-entry into the Mexico market. However, the Performance Chemicals segment continues to see volume declines, raising concerns about over-investment in capacity.

Why it matters — Investors should note that while topline growth is on track from oilfield and market expansion, ongoing weakness in the Performance Chemicals segment may weigh on overall returns for IOSP.

IOSP's Q2 Earnings Surpass Estimates on Broad-Based Growth

Zacks Investment Research · 7 Aug 2026positive

Innospec's second-quarter earnings surpassed estimates, driven by revenue growth across all three of its business segments. The company also maintains a debt-free balance sheet, which positions it for further investment.

Why it matters — The broad-based revenue growth and debt-free position indicate sound operational health and financial flexibility for future investment.

Is Innospec (IOSP) Stock Outpacing Its Basic Materials Peers This Year?

Zacks Investment Research · 7 Aug 2026neutral

The article compares Innospec's year-to-date stock performance against its basic materials peers, including Ingevity.

Why it matters — Investors tracking IOSP can gauge how its relative performance stacks up within the basic materials sector.

Innospec Inc. (IOSP) Q2 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Innospec Inc.'s Q2 2026 earnings call. The excerpt indicates the call took place and a transcript of it is now available.

Why it matters — An IOSP watcher would want to read the transcript for management's commentary on second-quarter 2026 performance and outlook.

Innospec Q2 Earnings Call Highlights

MarketBeat · 5 Aug 2026positive

Innospec reported higher second-quarter revenue and net income, with all three operating segments posting double-digit sales growth and operating-income gains, while the company continued repair and optimization work at its North Carolina Performance Chemicals facilities.

Why it matters — The broad-based double-digit growth across all segments and the ongoing facility improvements signal operational strength and capacity expansion at Innospec.

FAQ

Frequently asked questions about IOSP stock

What is the IOSP stock price forecast for 2026-2027?

The 3 Wall Street analysts covering Innospec, Inc. have a median 12-month price target of $100, with estimates ranging from $93 to $110. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is IOSP stock a buy right now?

Of the 3 analysts covering Innospec, Inc., 3 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Innospec, Inc. 86 out of 100 across roughly 4,600 US stocks as at 11 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank IOSP?

As at 11 Aug 2026, Innospec, Inc. ranks 86 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Revisions (91 of 100).

Will IOSP stock go up?

No one can know that. What the data says: the median 12-month target from 3 analysts implies +7.4% from the last close, and Ticker Nerd's factor model ranks Innospec, Inc. 86 out of 100 as at 11 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the IOSP stock forecast for 2030?

No analyst covering Innospec, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for IOSP are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $93 to $110 over the next 12 months.

How has IOSP stock performed over the past year?

Innospec, Inc. returned +15.3% over the 12 months to 12 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Innospec, Inc. do?

Innospec Inc. is a global specialty chemicals company that develops, manufactures, and supplies a broad range of chemical solutions to various industries.

What is the latest news on IOSP?

The most recent item we track (Seeking Alpha, 12 Aug 2026): "Innospec: Topline Is Growing As Expected". Innospec's topline grew as expected in Q2 2026, with revenue up 12% and beating estimates by $34.17 million, led by the oilfield segment's DRA adoption and re-entry into the Mexico market. However, the Performance Chemicals segment continues to see volume declines, raising concerns about over-investment in capacity.

Company

About Innospec, Inc.

Innospec Inc. is a global specialty chemicals company that develops, manufactures, and supplies a broad range of chemical solutions to various industries. With its primary function centered around providing performance-driven products, Innospec plays a vital role in the fuel, oilfield, and personal care sectors. This company is renowned for its fuel additives, which enhance engine performance and reduce emissions, as well as for its oilfield chemicals that optimize drilling and production operations. Additionally, Innospec's personal care and fragrance offerings enrich products in the beauty and fragrance industries. In the financial markets, Innospec Inc. holds significance by addressing niche demands within the chemical space, offering innovative solutions that balance technical prowess with environmental responsibility. Its operations span across different geographic markets, creating a diversified business model that underpins its stability and growth potential. By continually investing in research and development, Innospec sustains its competitive edge and meets evolving regulatory standards, ensuring robust participation in its respective industries. Founded in 1938, Innospec is headquartered in Englewood, Colorado, and is recognized for its commitment to sustainability and advanced chemical technology.

CEO Mr. Patrick S. Williams · 2,450 employees · United States · https://innospec.com